ACRUX LIMITED — Board/Management Information 2015

Jul 12, 2015

ACRUX (ACR) - ASX ANNOUNCEMENT 13 JULY 2015

APPOINTMENT OF PRODUCT DEVELOPMENT & TECHNICAL AFFAIRS DIRECTOR AND PORTFOLIO DIRECTOR

==> picture [482 x 10] intentionally omitted <==

Acrux (ASX: ACR) today announced the appointment of two leadership positions to support the Company’s growth strategy, focused on developing and commercialising products for the global pharmaceutical market.

The appointment of Felicia Colagrande to Product Development & Technical Affairs Director and Charles O’Sullivan to Portfolio Director will facilitate the focus on broadening and transitioning viable candidates through our product pipeline.

Acrux will update the market as various projects transition from the preclinical development stage.

Further information on the Company’s product pipeline and profiles for Felicia and Charles can be found by visiting www.acrux.com.au

Contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

About Acrux

• Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.

• The Acrux technology, used in marketed products including AXIRON[®] , Evamist[®] and Recuvyra™, is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposit drug through the skin for long acting delivery.

• Acrux has three products marketed by licensees in the USA, three products approved in Europe, and further products at earlier stages of development.

For further information on Acrux, visit www.acrux.com.au

==> picture [550 x 83] intentionally omitted <==